R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma.
Al-Sarayfi D, Meeuwes FO, Durmaz M, Issa DE, Brouwer RE, Beeker A, van Rhenen A, Mutsaers PGNJ, Böhmer LH, van der Poel MWM, Te Boome L, van Meerten T, Chamuleau MED, Zijlstra JM, Brink M, Nijland M.
Al-Sarayfi D, et al. Among authors: brink m.
Blood Cancer J. 2022 Sep 2;12(9):125. doi: 10.1038/s41408-022-00723-4.
Blood Cancer J. 2022.
PMID: 36055987
Free PMC article.
No abstract available.